{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:52:40Z","timestamp":1777452760526,"version":"3.51.4"},"reference-count":11,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Therapy"],"published-print":{"date-parts":[[2017,10]]},"abstract":"\n Background<\/jats:title>\n No published randomized controlled data on the use of direct-acting antivirals (DAA) in acute hepatitis C (AHC) coinfection exist. However, with the AHC epidemic ongoing among men who have sex with men (MSM) these are urgently needed.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n The CHAT study is a randomized controlled trial of pegylated interferon + ribavirin (PR) plus telaprevir (TVR) for 12\u201324 weeks versus PR alone for 24\u201348 weeks in the response-guided treatment of patients with AHC genotype (GT) 1 infection and HIV-1 coinfection in Germany and Great Britain.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n 34 patients were included: 15 were randomized to the PR arm (arm 1), 19 to the TVR + PR arm (arm 2). All patients were MSM, median age was 40 years. 55% had IL28B C\/C GT. Median baseline HCV RNA was 291,227 IU\/ml, median alanine aminotransferase was 105 U\/l. 85% received cART, all had baseline HIV RNA <40 copies\/ml. Overall sustained virological response (SVR\n 12<\/jats:sub>\n ) rate was 79.4% (27\/34). SVR\n 12<\/jats:sub>\n was seen in 12\/15 (80%) in arm 1 and in 15\/19 (79.8%) in arm 2. Of the four patients without SVR in arm 2, one experienced viraI breakthrough, two were non-responders; in one case HCV protease inhibitor (PI)-associated mutations were selected under TVR (V36M, R155K).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Due to moderate response rates and additional toxicities 1st generation HCV PIs should not be used in treating acute HCV. While not being licensed, recent study data and guidelines support the use of dual DAA therapy but optimal treatment duration in acute HCV needs further investigation.<\/jats:p>\n <\/jats:sec>","DOI":"10.3851\/imp3143","type":"journal-article","created":{"date-parts":[[2017,2,27]],"date-time":"2017-02-27T09:38:28Z","timestamp":1488188308000},"page":"619-623","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":8,"title":["Telaprevir-Containing Triple Therapy in Acute HCV Coinfection: The CHAT Study"],"prefix":"10.1177","volume":"22","author":[{"name":"the CHAT study group","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Boesecke","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Bonn University Hospital, Bonn, Germany"},{"name":"German Centre for Infection Research (DZIF), Partner Site Cologne-Bonn, Bonn, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gurmit K Jagjit","family":"Singh","sequence":"additional","affiliation":[{"name":"Chelsea and Westminster Hospital, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan H-A","family":"Scholten","sequence":"additional","affiliation":[{"name":"Praxis Hohenstaufenring, Cologne, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Lutz","sequence":"additional","affiliation":[{"name":"Infektiologikum, Frankfurt\/Main, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Baumgarten","sequence":"additional","affiliation":[{"name":"zipb, Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan M","family":"Schneeweiss","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Bonn University Hospital, Bonn, Germany"},{"name":"Praxis Hohenstaufenring, Cologne, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Trein","sequence":"additional","affiliation":[{"name":"Gemeinschaftspraxis Schwabstrasse, Stuttgart, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Rausch","sequence":"additional","affiliation":[{"name":"\u00c4rztezentrum Nollendorfplatz, Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Ingiliz","sequence":"additional","affiliation":[{"name":"zipb, Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen K","family":"Rockstroh","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Bonn University Hospital, Bonn, Germany"},{"name":"German Centre for Infection Research (DZIF), Partner Site Cologne-Bonn, Bonn, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Nelson","sequence":"additional","affiliation":[{"name":"Chelsea and Westminster Hospital, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2016,10,1]]},"reference":[{"key":"bibr1-IMP3143","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-015-0856-9"},{"key":"bibr2-IMP3143","unstructured":"Boesecke C., Nelson M., Ingiliz P. Does the availability of new DAAs influence treatment uptake in acute hepatitis C in HIV coinfection?\n 22nd Conference on Retroviruses and Opportunistic Infections\n . 23\u201326 February 2015, Seattle, WA, USA. Abstract 670."},{"key":"bibr3-IMP3143","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12848"},{"key":"bibr4-IMP3143","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.09.004"},{"key":"bibr5-IMP3143","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.12.004"},{"key":"bibr6-IMP3143","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit799"},{"key":"bibr7-IMP3143","unstructured":"Naggie S., Cooper C., Saag M.S. Ledipasvir\/sofosbuvir for 12 weeks in patients coinfected with HCV and HIV-1.\n 22nd Conference on Retroviruses and Opportunistic Infections\n . 23\u201326 February 2015, Seattle, WA, USA. Abstract 152LB."},{"key":"bibr8-IMP3143","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28844"},{"key":"bibr9-IMP3143","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(17)30003-1"},{"key":"bibr10-IMP3143","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)30408-X"},{"key":"bibr11-IMP3143","unstructured":"European AIDS Clinical Society (EACS). Guidelines Version 8.1. October 2016. (Accessed 8 February 2017.) Available from http:\/\/www.eacsociety.org\/guidelines\/eacs-guidelines\/eacs-guidelines.html."}],"container-title":["Antiviral Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3851\/IMP3143","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3851\/IMP3143","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:52:17Z","timestamp":1777380737000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3851\/IMP3143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,1]]},"references-count":11,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["10.3851\/IMP3143"],"URL":"https:\/\/doi.org\/10.3851\/imp3143","relation":{},"ISSN":["1359-6535","2040-2058"],"issn-type":[{"value":"1359-6535","type":"print"},{"value":"2040-2058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,1]]}}}